SCHEMBL30714734

SCHEMBL30714734

Cn1ccc(NC(=O)c2c3cc(OCc4ccccc4)ccc3nn2C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NMT1 P30419 1/20 0.42
HTR3A P46098 2/20 0.42
MMP13 P45452 1/20 0.42
SCD O00767 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HDAC3 O15379 1/20 0.41
APP P05067 1/20 0.41
ACHE P22303 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714697 0.85 HPGDS (0.44) HPGDSKMT2ASMN1; SMN2SCDNPC1
SCHEMBL30714576 0.82 HPGDS (0.42) HPGDSSMN1; SMN2SCDNPC1RAB9A
SCHEMBL26696088 0.82 SRD5A2 (0.50) MEN1KMT2ASMN1; SMN2NMT1NPC1
SCHEMBL30714553 0.81 GCK (0.41) HPGDSSCDNPC1RAB9A
SCHEMBL30714592 0.80 EGLN2 (0.45) MEN1KMT2ATSHRSMN1; SMN2NMT1
SCHEMBL30714665 0.79 NMT1 (0.43) MEN1KMT2ATSHRSMN1; SMN2NMT1
SCHEMBL30714708 0.79 EGLN2 (0.47) MEN1KMT2ATSHRSMN1; SMN2NMT1
SCHEMBL1426983 0.79 GCK (0.61) HPGDSMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL26696011 0.79 NMT1 (0.48) MEN1KMT2ASMN1; SMN2NMT1NPC1
SCHEMBL24470562 0.78 CASP3 (0.62) MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 HPGDS 671/4885MEN1 1744/4885KMT2A 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.